AveXis Inc (AVXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
78
About the Report
About the Report
Summary
AveXis Inc (AveXis), formerly BioLife Cell Bank Inc, is a biotechnology company that develops innovative treatments for rare and potentially fatal neurological genetic diseases. The company offers AVXS-101, a proprietary gene therapy candidate in phase 1 targeted at the treatment of spinal muscular atrophy. Its AVXS-101 received orphan drug designation for the treatment of all types of SMA from the US FDA; fast track designation for the treatment of SMA Type 1; and breakthrough therapy designation for the treatment of SMA Type 1 in pediatric patients. It works in collaboration with various academic institutes and research centers to advance its investigational product candidates. AveXis is headquartered in Bannockburn, Illinois, the US.
AveXis Inc (AVXS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
AveXis Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AveXis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AveXis Inc, Medical Devices Deals, 2012 to YTD 2018 10
AveXis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AveXis Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
AveXis Raises USD65 Million in Venture Financing 13
AveXis Raises USD10 Million in Series C Financing Round 15
Partnerships 16
AveXis Enters into Licensing Agreement with Genethon and Centre National de la Recherche Scientifique 16
Licensing Agreements 17
AveXis Enters into Licensing Agreement with Regenxbio 17
AveXis Enters into Licensing Agreement with Nationwide Children's Hospital for Development of Rett syndrome 19
AveXis Enters into Licensing Agreement with Nationwide Children's Hospital for Development of Amyotrophic Lateral Sclerosis 20
Asklepios BioPharma Enters into Licensing Agreement with AveXis 21
AveXis Amends Licensing Agreement With ReGenX Biosciences 22
AveXis Amends Licensing Agreement with Nationwide Children's Hospital 23
Equity Offering 24
AveXis Raises USD460 Million in Public Offering of Shares 24
AveXis Raises USD287.8 Million in Public Offering of Shares 26
AveXis Raises USD146.6 Million in Public Offering of Shares 28
AveXis Completes Underwriter's Exercise of Over-Allotment Option of IPO 30
AveXis Raises USD2 Million in Private Placement of Shares and Warrants 31
Debt Offering 32
AveXis Raises USD0.5 Million in Private Placement of 8% Notes 32
Acquisition 33
Novartis Acquires AveXis for USD8.7 Billion 33
AveXis Inc-Key Competitors 35
AveXis Inc-Key Employees 36
AveXis Inc-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
May 03, 2018: AveXis Reports First Quarter 2018 Financial and Operating Results 38
Feb 27, 2018: AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results 40
Nov 09, 2017: AveXis Reports Third Quarter 2017 Financial and Operating Results 42
Aug 10, 2017: AveXis Reports Second Quarter 2017 Financial and Operating Results 44
May 11, 2017: AveXis Reports First Quarter 2017 Financial and Operating Results 46
Corporate Communications 48
Feb 15, 2017: AveXis Appoints Rick Modi as Senior Vice President and Chief Business Officer 48
Product Approvals 49
Mar 27, 2018: AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1 49
Jan 04, 2018: AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1 50
Jun 14, 2017: AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101 51
Jan 31, 2017: AveXis Gene Therapy AVXS-101 Granted Access into EMA PRIME Program for Spinal Muscular Atrophy Type 1 53
Clinical Trials 54
May 08, 2018: AveXis Issues Community Statement on the SPR1NT Trial 54
Apr 25, 2018: AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3 55
Apr 24, 2018: AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology 57
Apr 19, 2018: AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology 59
Jan 30, 2018: AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients 60
Jan 16, 2018: AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy 61
Dec 13, 2017: AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101 62
Nov 01, 2017: AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1 64
Oct 03, 2017: AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society 66
Sep 29, 2017: AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process 67
Apr 25, 2017: AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology 69
Apr 18, 2017: AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology 71
Mar 16, 2017: AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results 72
Mar 09, 2017: AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 75
Mar 02, 2017: AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting 76
Feb 06, 2017: AveXis Announces Single-Arm Design for European Pivotal Study of AVXS-101 in SMA Type 1 Patients 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78
List of Figure
List of Figures
AveXis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AveXis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AveXis Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
AveXis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AveXis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AveXis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
AveXis Inc, Medical Devices Deals, 2012 to YTD 2018 10
AveXis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AveXis Raises USD65 Million in Venture Financing 13
AveXis Raises USD10 Million in Series C Financing Round 15
AveXis Enters into Licensing Agreement with Genethon and Centre National de la Recherche Scientifique 16
AveXis Enters into Licensing Agreement with Regenxbio 17
AveXis Enters into Licensing Agreement with Nationwide Children's Hospital for Development of Rett syndrome 19
AveXis Enters into Licensing Agreement with Nationwide Children's Hospital for Development of Amyotrophic Lateral Sclerosis 20
Asklepios BioPharma Enters into Licensing Agreement with AveXis 21
AveXis Amends Licensing Agreement With ReGenX Biosciences 22
AveXis Amends Licensing Agreement with Nationwide Children's Hospital 23
AveXis Raises USD460 Million in Public Offering of Shares 24
AveXis Raises USD287.8 Million in Public Offering of Shares 26
AveXis Raises USD146.6 Million in Public Offering of Shares 28
AveXis Completes Underwriter's Exercise of Over-Allotment Option of IPO 30
AveXis Raises USD2 Million in Private Placement of Shares and Warrants 31
AveXis Raises USD0.5 Million in Private Placement of 8% Notes 32
Novartis Acquires AveXis for USD8.7 Billion 33
AveXis Inc, Key Competitors 35
AveXis Inc, Key Employees 36
AveXis Inc, Subsidiaries 37
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.